News & Events

FDA clears Magstim transcranial magnetic stimulation for obsessive compulsive disorder

Non-invasive Treatment Cleared for Treating Patients Diagnosed with OCD MINNEAPOLIS, Minn. – (January 18, 2023) – Magstim, a global leader in neuroscience research and Transcranial Magnetic Stimulation (TMS) solutions for mental health, announced today that the FDA has cleared the Horizon 3.0 (with…
Magstim Insights Ready to Read Now

Magstim Insights Ready to Read Now

Have you seen the latest issue of Magstim Insights?Click to read our inspiration edition.
NEW MAGSTIM ANALYTICS SOFTWARE OFFERS POWERFUL TMS DATA FOR PRACTICES, TREATERS AND DEVICE REPORTING

NEW MAGSTIM ANALYTICS SOFTWARE OFFERS POWERFUL TMS DATA FOR PRACTICES, TREATERS AND DEVICE REPORTING

HIPAA Compliant TMS software provides new level of data designed to improve quality control metrics for patients and practices MINNEAPOLIS, Minn. & Carmarthenshire, UK – (April 28, 2022) – Magstim, the global leader in neuroscience research and treatment for mental…

Welcony Inc Appoints Ronnie Stolec-Campo To Lead Global Business

Welcony Inc, a global neurotechnology leader, announces that Ronnie Stolec-Campo will now lead the business. As CEO, she succeeds Lothar Krinke, PhD, who announced his departure from the organization. Stolec-Campo will not continue her role as Chief Financial Officer for…

Magstim Horizon 3.0 First Impressions Video

Listen to what these top TMS clinical professionals had to say about the new Magstim H3.0 Thanks to John Cavanagh and Carla Weatherford, Restore-Brain and to Lilly Sanchez, Genesis Behavioral Health. https://www.youtube.com/watch?v=nXfv4TlQYLY
GROUNDBREAKING STUDY: After TMS treatment, 65.3% of Veterans with co-morbid PTSD and MDD demonstrated clinically meaningful reduction

GROUNDBREAKING STUDY: After TMS treatment, 65.3% of Veterans with co-morbid PTSD and MDD demonstrated clinically meaningful reduction

In the largest study of its kind to date, medical researchers with the U.S. Department of Veterans Affairs (VA) supports the effectiveness and safety of transcranial magnetic stimulation for veterans with MDD and PTSD using standard clinical approaches. As published in…
Magstim EGI Academy: Integrated Brain Stimulation Solutions Utilizing TMS, EEG and TES

Magstim EGI Academy: Integrated Brain Stimulation Solutions Utilizing TMS, EEG and TES

Thank you to everyone who attended our webinar with Dr Alix Thomson covering Integrated brain stimulation solutions utilizing TMS, EEG and TES. Integration of different brain stimulation and neuroimaging techniques has widespread implications for both research and clinical applications. In this webinar,…
Magstim Awarded FDA (510K) Clearance for Advanced Transcranial Magnetic Stimulation (TMS) Platform Horizon 3.0

Magstim Awarded FDA (510K) Clearance for Advanced Transcranial Magnetic Stimulation (TMS) Platform Horizon 3.0

New Class of Navigated TMS Delivers Customized, Repeatable Treatments Improving Patient Care and Clinical Efficiencies MINNEAPOLIS, Minn. & Carmarthenshire, UK -- (Oct. 28, 2021) – Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded…
Autism Biomarkers and Research using TMS and HD-EEG – Available Now

Autism Biomarkers and Research using TMS and HD-EEG – Available Now

If you missed out on our Autism Biomarkers and Research using TMS and HD-EEG webinar with James McPartland, PhD, and Kim Hollingsworth Taylor then you can catch up now. Watch Now Dr McPartland, Professor of Child Psychiatry and Psychology Director,…

Keep up to date

By signing up you are confirming that you have read, understood and accept our Privacy Policy